Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Cx11
2. 5-[[(1-cyclopentyl-3-piperidyl)methyl-[2-(1-piperidyl)ethyl]amino]methyl]-2-methoxy-phenol
| Molecular Weight | 429.6 g/mol |
|---|---|
| Molecular Formula | C26H43N3O2 |
| XLogP3 | 4.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 9 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 39.2 |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 507 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The Series D financing for CX11, a miscellaneous product targeting the GLP-1 receptor, will advance research in obesity.
Lead Product(s): CX11,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: RTW Investments|SR One|Undisclosed|RA Capital Management|HBM Healthcare Investments|Undisclosed|Undisclosed|Invus|Undisclosed|Undisclosed
Deal Size: $287.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing January 22, 2026
Lead Product(s) : CX11,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : RTW Investments|SR One|Undisclosed|RA Capital Management|HBM Healthcare Investments|Undisclosed|Undisclosed|Invus|Undisclosed|Undisclosed
Deal Size : $287.0 million
Deal Type : Series D Financing
Corxel Raises $287M to Advance Cardiometabolic Pipeline with Oral GLP-1 Agonist
Details : The Series D financing for CX11, a miscellaneous product targeting the GLP-1 receptor, will advance research in obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 22, 2026
Details:
CX11 (VCT220) is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of diabetes mellitus, type 2.
Lead Product(s): CX11,Inapplicable
Therapeutic Area: Endocrinology Brand Name: CX11
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 14, 2026
Lead Product(s) : CX11,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Details : CX11 (VCT220) is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of diabetes mellitus, type 2.
Product Name : CX11
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 14, 2026
Details:
CX11 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Lead Product(s): CX11,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2025
Lead Product(s) : CX11,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy & Safety of CX11 Tablets in Overweight & Obese Participants
Details : CX11 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2025
Details:
CX11, an investigational oral once-daily small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). It is being investigated for obesity and overweight.
Lead Product(s): CX11,Inapplicable
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2025
Lead Product(s) : CX11,Inapplicable
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CORXEL gets FDA Go-Ahead for Phase 2 Trial of CX11 in Obesity
Details : CX11, an investigational oral once-daily small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). It is being investigated for obesity and overweight.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
27
PharmaCompass offers a list of CX11 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right CX11 manufacturer or CX11 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred CX11 manufacturer or CX11 supplier.
A CX11 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CX11, including repackagers and relabelers. The FDA regulates CX11 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CX11 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A CX11 supplier is an individual or a company that provides CX11 active pharmaceutical ingredient (API) or CX11 finished formulations upon request. The CX11 suppliers may include CX11 API manufacturers, exporters, distributors and traders.
CX11 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CX11 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right CX11 GMP manufacturer or CX11 GMP API supplier for your needs.
A CX11 CoA (Certificate of Analysis) is a formal document that attests to CX11's compliance with CX11 specifications and serves as a tool for batch-level quality control.
CX11 CoA mostly includes findings from lab analyses of a specific batch. For each CX11 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CX11 may be tested according to a variety of international standards, such as European Pharmacopoeia (CX11 EP), CX11 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CX11 USP).
